A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
The facility will manufacture its Herceptin biosimilar, Tuznue
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Subscribe To Our Newsletter & Stay Updated
